Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
The cough and respiratory health therapeutics market was valued at USD 24.80 Billion in 2025 and is projected to reach USD 50.64 Billion by 2035, growing at a CAGR of 7.40%. Growth is supported by recurring seasonal respiratory infections, a large non-prescription base that sustains steady volumes, rising recognition of refractory chronic cough as a treatable condition, and a gradual shift toward inhaled and premium formulations.
Patent activity spans P2X3 receptor antagonists for refractory chronic cough, neuromodulators acting on the cough reflex, mucolytic and expectorant formulations, and inhaled and nebulised delivery systems. Regulatory validation came from the approval of gefapixant in the European Union and Japan and from late-stage trials of camlipixant, which have encouraged originators to widen filings on dosing, salt forms and indications, while consumer health companies continue to file on taste-masked, fast-acting and combination formats.
This Cough and Respiratory Health Therapeutics Patent Landscape Analysis Report provides a structured view of patent filing trends, leading assignees, jurisdictions, technology clusters and competitive positioning across therapeutics used to treat acute and chronic cough and related respiratory conditions.
The cough and respiratory health therapeutics market is experiencing strong growth, driven by recurring seasonal respiratory illness, recognition of refractory chronic cough as a distinct condition, and consumer demand for faster-acting formats. Gefapixant, the first P2X3 receptor antagonist approved for refractory chronic cough in several markets, showed that a prescription therapy can reach patients who were long treated with off-label drugs.
Patent activity is accelerating, with 310+ cough and respiratory health therapeutics patents granted in 2025, reflecting strong innovation momentum in P2X3 receptor antagonists for refractory chronic cough, neuromodulators that act on the cough reflex, mucolytic and expectorant formulations for productive cough, and inhaled and nebulised delivery of respiratory therapeutics.
Top assignees in the cough and respiratory health therapeutics patent landscape include Merck, Shionogi, GlaxoSmithKline, Haleon, and Reckitt, with the United States, China, and Europe as the dominant patent jurisdictions.
Cough is among the most common reasons for consultation in primary care and for purchases in community pharmacies, and the market for cough and respiratory health therapeutics reflects that breadth. Demand is split between a very large, well-established base of non-prescription syrups, lozenges and tablets used for self-care of acute illness, and a smaller prescription segment serving chronic and refractory patients. Seasonal infections, air pollution, allergies and smoking-related disease keep volumes steady across regions, while ageing populations increase the number of people with persistent respiratory symptoms. Consumers favour fast-acting, better-tasting and combination formats, and clinicians increasingly look for targeted therapies when cough lasts beyond eight weeks.
The market growth is driven by prescription therapies for refractory chronic cough, which add higher-priced treatments to a large non-prescription base and lift value faster than volume. Gefapixant gained approval in the European Union and Japan, and camlipixant, which GlaxoSmithKline obtained through its 2023 acquisition of BELLUS Health, has been tested in phase 3 trials. Chronic cough, defined as lasting more than eight weeks, affects around 10 percent of adults in several population surveys, which points to a large untreated population. The overall pace is moderate because the non-prescription base is mature, price-sensitive and led by established brands, so incremental growth comes mainly from premium formats and newly approved prescription options.
A chronic cough prevalence of around 10 percent of adults indicates a large pool of people who live with symptoms for months, and the small share who reach specialist care shows how much room remains for diagnosis and prescription treatment. The gefapixant phase 3 programmes enrolled about 730 patients in COUGH-1 and about 1,300 in COUGH-2, and their reduction in cough frequency indicates that the P2X3 receptor is a validated target, which encourages other developers to file on it. Because non-prescription products are bought at pharmacies without a prescription, volumes follow seasonal infection waves, which supports steady revenue but limits pricing power. Together these features describe a market with a large foundation and growth concentrated in newer therapies.
Filing intensity in cough and respiratory health therapeutics follows two distinct investment patterns. Pharmaceutical companies concentrate spending on P2X3 receptor antagonists and related neuromodulators, where clinical programmes are costly and patent claims cover compounds, salt forms and dosing. Consumer health companies, including Haleon and Reckitt, invest in brand extensions and file more narrowly on formulations, delivery formats and flavour masking. The acquisition of BELLUS Health by GlaxoSmithKline in 2023 brought camlipixant into a larger portfolio with broad global filing capacity, and it shows how late-stage assets are moving toward companies able to fund pivotal trials.
More than 6,400 patent families related to cough and respiratory health therapeutics were identified across the landscape. Filing peaked between roughly 2021 and 2024, when applications on P2X3 receptor antagonists and related neuromodulators grew alongside late-stage trial readouts. The largest clusters cover P2X3 receptor antagonists for refractory chronic cough, neuromodulators that act on the cough reflex, mucolytic and expectorant formulations for productive cough, and inhaled and nebulised delivery of respiratory therapeutics, while antihistamine and decongestant combinations form a steady second tier. Older formulation families remain numerous because taste masking, sustained release and ready-to-use liquids are filed continuously by consumer health companies.
The overlap between a large and recurring patient base and the concentration of new filings on refractory chronic cough and inhaled delivery shows that demand is steering patent coverage toward higher-value therapies.
This report analyses patent activity and market trends associated with cough and respiratory health therapeutics across the United States, Europe, China, Japan, South Korea, India and international filings made through the World Intellectual Property Organization (WIPO). Coverage includes antitussives, expectorants, mucolytics, bronchodilators, antihistamines and decongestants used to relieve cough and related respiratory symptoms, drawn from national offices and regional authorities. Market context reflects use in Hospitals, Specialty Respiratory Clinics, Retail and Community Pharmacies, Home Care Consumers and Academic and Research Institutes, linking patent coverage to treatment demand in each region.
The scope includes antitussives, expectorants and mucolytics, P2X3 receptor antagonists and neuromodulators, bronchodilators and inhaled agents, and antihistamines and decongestants as therapeutic classes. Cough types considered are acute cough, chronic refractory cough, productive cough, dry cough, and allergic and post-infectious cough. Dosage forms covered are syrups and oral liquids, tablets and capsules, lozenges and pastilles, inhalers and nebulisers, and nasal sprays and other forms, and patents are grouped by technology cluster to show where innovation concentrates.
The analysis includes patent activity from research-based pharmaceutical companies developing prescription therapies for chronic cough, consumer health companies that market non-prescription cough and cold ranges, and specialist developers of inhaled and nebulised delivery systems. Generic and regional manufacturers that file on formulations and combinations are also covered, as are universities, hospitals and clinical investigators working on cough reflex mechanisms, airway sensory nerves and cough measurement. Suppliers of excipients, devices and inhaler components are included where their filings relate to cough and respiratory health therapeutics.
The report will cover the following sections in detail:
Analysis by Therapeutic Class
Analysis by Cough Type
Analysis by Dosage Form
Cough and Respiratory Health Therapeutics Patent Filing Trend Analysis
The evolution of patent filings for cough and respiratory health therapeutics shows a long phase built on antitussive and expectorant formulations, including dextromethorphan and guaifenesin products, followed by improvements in delivery such as sustained-release liquids, lozenges and inhaled systems. From the early 2010s, research on airway sensory nerves brought a new class of P2X3 receptor antagonists, and filings on these compounds, their salts and their uses increased once phase 3 results arrived. Consumer health filings have stayed steady, focusing on taste masking, combinations and convenient formats. Annual grants of more than 310 patents in 2025 indicate a substantial base of enforceable rights and a continuing pipeline of applications.
Patent filings increased at an estimated annual growth rate of approximately 8% between 2020 and 2024. Applications on P2X3 receptor antagonists and neuromodulators grew fastest, supported by late-stage clinical data and regulatory decisions in Europe and Japan. Inhaled and nebulised delivery filings also expanded as developers looked for ways to place respiratory therapeutics directly in the airway, while mucolytic and expectorant formulation filings grew at a slower, steadier pace. Applicants broadened claims to cover methods of treating specific patient groups, because use claims extend protection beyond the original compound.
Among the players with cough and respiratory health therapeutics patent families, new entrants have been identified, which can be either established companies or startups developing novel technology in the field. Some of the major companies mentioned in this report (a non-exhaustive list) are as follows:
Merck holds a leading position in cough and respiratory health therapeutics through its work on P2X3 receptor antagonists, led by gefapixant, which it developed for refractory or unexplained chronic cough and which is marketed as Lyfnua where approved. The product received approval in the European Union and Japan, while the United States Food and Drug Administration declined to approve it after reviewing the COUGH-1 and COUGH-2 phase 3 programmes. Filings cover compound families, crystalline and salt forms, dosing regimens and patient selection. The intellectual property strategy relies on layered protection around the receptor target and its clinical use. Commercially, the company is positioned as the first mover in a prescription segment that remains small beside the non-prescription cough market but offers durable pricing in specialist care.
Shionogi combines a long-standing presence in Japanese cough and cold medicines with research on the cough reflex. Its respiratory range includes antitussive products sold in Japan, and its pipeline has included S-600918, a P2X3 receptor antagonist studied for refractory chronic cough. The company is also known for anti-infective products for respiratory infections, notably baloxavir marboxil (Xofluza) for influenza, which links its filings to the infection side of respiratory illness. Regulatory standing is strongest in Japan, where it holds marketing authorisations for several respiratory products. Its intellectual property strategy pairs compound and formulation filings with licensing partnerships, and commercially it is positioned as a Japan-centred developer that uses partners to reach wider markets.
Other companies include GlaxoSmithKline, Haleon, and Reckitt.
The leading assignees, Merck, Shionogi, GlaxoSmithKline, Haleon and Reckitt, hold a modest share of analysed patent families, indicating a fragmented landscape in which no single owner dominates. Merck holds coverage on gefapixant and related P2X3 receptor antagonists, while Shionogi combines cough reflex research with respiratory anti-infective products. GlaxoSmithKline spans prescription respiratory medicines and camlipixant, and Haleon and Reckitt file mainly on non-prescription formulations, delivery formats and brand extensions in cough, cold and throat care. A long tail of regional manufacturers and academic groups contributes claims on herbal, combination and inhaled products.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
The report assesses patent activity across major jurisdictions, including:
The United States is the largest single jurisdiction for cough and respiratory health therapeutics, reflecting the size of its prescription and non-prescription markets, the value of regulatory exclusivity and the strength of patent enforcement. China follows as a major filing centre, driven by domestic pharmaceutical manufacturers, traditional medicine producers that patent herbal cough formulas, and a large population affected by respiratory disease. Europe is supported by European Patent Office filings and national validations, helped by the European approval of gefapixant. Japan holds a distinctive position through Shionogi and other domestic firms with long-established cough and cold ranges, while South Korea and India show smaller but growing activity linked to local manufacturers, and WIPO filings reveal which families applicants plan to take into several markets.
The patent landscape is segmented by the technology categories most closely associated with cough and respiratory health therapeutics, which include:
Among these, P2X3 receptor antagonists for chronic cough lead recent patent activity. Applicants are filing on selective compounds that spare taste function, crystalline and salt forms, dosing regimens, and methods of treating patients with refractory or unexplained cough. Growth in this cluster has outpaced formulation filings since late-stage trials and approvals in Europe and Japan indicated that targeting airway sensory nerves reduces cough frequency, and loss of taste, the main adverse effect seen with gefapixant, is the problem that newer selective molecules aim to avoid.
The cough and respiratory health therapeutics market is competitive but divided between two types of player. Research-based companies including Merck and GlaxoSmithKline compete to establish the first and best prescription options for refractory chronic cough, while consumer health groups such as Haleon and Reckitt compete on brand strength, pharmacy distribution and format. Shionogi occupies a position between the two, combining a Japanese consumer presence with research on the cough reflex. Gefapixant, approved in Europe and Japan but not in the United States, shows how regulatory outcomes can differ by region. Filings from regional manufacturers in China and India show that formulation and combination products remain open to new entrants.
Companies are focusing on:
Emerging innovation themes include highly selective P2X3 receptor antagonists that avoid taste disturbance, other targets on airway sensory nerves such as the neurokinin-1 receptor and sodium channels, and inhaled delivery that places drugs directly in the airway. Interest is growing in treatments for cough associated with idiopathic pulmonary fibrosis, where cough is frequent and disabling, and in acoustic tools that count coughs objectively for clinical trials. Consumer health developers are exploring natural-origin actives, sugar-free paediatric liquids and fast-dissolving formats.
The patent landscape for cough and respiratory health therapeutics maps how innovation is distributed across therapeutic classes, cough types and dosage forms in more than 7,600 patent families, and it identifies the assignees and jurisdictions where protection is concentrated. Filings on P2X3 receptor antagonists and neuromodulators show where prescription investment is directed, while the dense formulation families of non-prescription products indicate where freedom to operate depends on narrow claims and expiry timelines. Together, the findings give developers, investors and consumer health companies a structured view of competitive positions.
The landscape provides actionable intelligence for the following nine uses:
Patent research was conducted across major patent databases, including national and regional office records and international filings published under the Patent Cooperation Treaty. Search strategies combined Cooperative Patent Classification codes for antitussive, expectorant, mucolytic and inhaled respiratory preparations with keyword queries on cough types, therapeutic classes and dosage forms. Records were gathered through the latest complete publication period, and equivalent filings were consolidated into patent families so that each invention was counted once.
Screening removed duplicate families and filings with no relevance to cough and respiratory health therapeutics. Remaining records were reviewed and classified by technology cluster, therapeutic class, cough type, dosage form, assignee and jurisdiction. Assignee names were standardised so that subsidiaries, successor companies and name variants were attributed to a single owner, and legal status was used to distinguish granted patents from pending applications.
Market analysis supported the interpretation of patent trends through review of regulatory decisions, clinical trial publications, company disclosures and pharmacy sales data. Patent activity was compared with approval timelines and product launches to show how innovation tracks demand. Findings were cross-checked across sources, and analyst estimates are described as approximate where exact counts were not available.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
EMR's Cough and Respiratory Health Therapeutics Patent Landscape Analysis provides a comprehensive assessment of patent filings, innovation clusters, assignee portfolios, and geographic filing patterns across the cough and respiratory health therapeutics landscape. The report identifies 6,400+ patent families, evaluates leading jurisdictions including the United States, China, and Europe, and profiles the top assignees by portfolio size.
The global cough and respiratory health therapeutics market was valued at USD 24.80 Billion in 2025. The market is projected to reach USD 50.64 Billion by 2035, expanding at a CAGR of 7.40% during 2026 - 2035.
The report analyses approximately 6,400+ patent families related to cough and respiratory health therapeutics. These include filings from the United States, China, Europe, and international WIPO filings.
Key companies operating within the landscape include Merck, Shionogi, GlaxoSmithKline, Haleon, and Reckitt, among others. These organisations collectively account for a significant portion of patent activity analysed in this report.
The report evaluates patent activity across the United States, Europe, China, Japan, South Korea, India, and international WIPO filings. The United States is the largest single jurisdiction for cough and respiratory health therapeutics, with 2,300+ patents associated with it across the 6,400+ patent families analysed.
Yes. The report scope can be customised based on geography, technology segment, assignee selection, time period, or specific innovation cluster focus. Readers can contact the EMR team to scope a customised study, such as a tailored patent landscape focused on P2X3 receptor antagonists, inhaled delivery systems or specific assignees and jurisdictions in cough and respiratory health therapeutics.
Patent landscape analysis helps organisations understand innovation trends, competitive activity, technology whitespace, and IP risk across a defined domain. For cough and respiratory health therapeutics, this report supports strategic decisions in R&D prioritisation, licensing evaluation, competitive benchmarking, and market entry planning.
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Analysis by Therapeutic Class |
|
|
Analysis by Cough TypeAnalysis by Cough Type |
|
|
Analysis by Dosage Form |
|
|
Analysis by End User |
|
|
Key Players Mentioned |
|
|
Geographies Covered |
|
Mini Report
One User
USD 2,699
USD 2,429
tax inclusive*
Single User License
One User
USD 4,299
USD 3,869
tax inclusive*
Five User License
Five User
USD 5,799
USD 4,949
tax inclusive*
Corporate License
Unlimited Users
USD 6,999
USD 5,949
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.